[Abstract Only] Randomized Trial: Eplerenone Not Beneficial for Chronic Central Serous Chorioretinopathy in Patients with Active, Previously Untreated Disease
26 Jan, 2020 | 22:27h | UTCEplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial – The Lancet (link to abstract – $ for full-text)
Commentary: Researchers find drug used widely to treat eye condition has ‘no benefit’ – University of Bristol (free)